INT110245

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 2003
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 11
Total Number 16
Disease Relevance 8.29
Pain Relevance 3.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (SNCA) oxidoreductase activity (SNCA) cell death (SNCA)
extracellular region (SNCA) histone binding (SNCA) plasma membrane (SNCA)
Anatomy Link Frequency
substantia nigra 1
neuronal 1
SK-N-MC 1
striatum 1
SNCA (Homo sapiens)
SNCA - A53T (5)
Pain Link Frequency Relevance Heat
Dopamine 170 100.00 Very High Very High Very High
Substantia nigra 314 99.52 Very High Very High Very High
Paracetamol 11 99.24 Very High Very High Very High
induced neuropathy 3 97.72 Very High Very High Very High
midbrain 21 75.76 Quite High
Ventral tegmentum 4 75.36 Quite High
Opioid 2 75.00 Quite High
imagery 11 67.60 Quite High
Nucleus accumbens 1 62.40 Quite High
Neuritis 1 34.12 Quite Low
Disease Link Frequency Relevance Heat
Disease 552 100.00 Very High Very High Very High
Alzheimer's Dementia 38 100.00 Very High Very High Very High
Neuroblastoma 7 99.62 Very High Very High Very High
Toxicity 77 99.56 Very High Very High Very High
Neurodegenerative Disease 40 98.28 Very High Very High Very High
Neuropathic Pain 3 97.72 Very High Very High Very High
Stress 26 97.32 Very High Very High Very High
Parkinson's Disease 421 96.60 Very High Very High Very High
Opiate Addiction 4 95.72 Very High Very High Very High
Death 29 95.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants.
Gene_expression (transfected) of alpha-synuclein associated with neuroblastoma, dopamine and disease
1) Confidence 0.77 Published 2003 Journal Neurosci. Lett. Section Title Doc Link 12727333 Disease Relevance 0.70 Pain Relevance 0.21
Using three independent and established neurodegenerative models in C. elegans, we assayed for acetaminophen-dependent rescue in response to: (1) over-expression of the PD-associated protein, alpha-synuclein; (2) acute exposure to 6-hydroxydopamine (6-OHDA); (3) excess intracellular DA production due to over-expression of the DA biosynthetic enzyme, tyrosine hydroxylase (TH).
Gene_expression (over-expression) of alpha-synuclein associated with dopamine, paracetamol, disease and neurodegenerative disease
2) Confidence 0.75 Published 2008 Journal Neurosci. Lett. Section Abstract Doc Link 18514411 Disease Relevance 0.84 Pain Relevance 0.72
SK-N-MC neuroblastoma cells were transiently transfected with either wt alpha-synuclein, or its mutants, and their abilities to protect against oxidative stress were assessed.
Gene_expression (transfected) of alpha-synuclein in SK-N-MC associated with stress and neuroblastoma
3) Confidence 0.67 Published 2003 Journal Neurosci. Lett. Section Abstract Doc Link 12727333 Disease Relevance 0.63 Pain Relevance 0.21
These results show an absence of protective effects for the A30P/A53T mutants, and a differential cytoprotective role of alpha-synuclein against oxidants, which varies according to expression levels.
Gene_expression (expression) of alpha-synuclein
4) Confidence 0.67 Published 2003 Journal Neurosci. Lett. Section Abstract Doc Link 12727333 Disease Relevance 0.57 Pain Relevance 0.18
Similarly, mutations in the SNCA, or Synuclein-Alpha (non-A4 component of amyloid precursor) gene [40] as well as the overproduction of ?
Gene_expression (overproduction) of Synuclein-Alpha associated with alzheimer's dementia
5) Confidence 0.67 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2965495 Disease Relevance 0.66 Pain Relevance 0
Using three independent and established neurodegenerative models in C. elegans, we assayed for acetaminophen-dependent rescue in response to: (1) over-expression of the PD-associated protein, alpha-synuclein; (2) acute exposure to 6-hydroxydopamine (6-OHDA); (3) excess intracellular DA production due to over-expression of the DA biosynthetic enzyme, tyrosine hydroxylase (TH).
Gene_expression (over-expression) of alpha-synuclein associated with dopamine, paracetamol, disease and neurodegenerative disease
6) Confidence 0.65 Published 2008 Journal Neurosci. Lett. Section Abstract Doc Link 18514411 Disease Relevance 0.84 Pain Relevance 0.72
-synuclein gene (SNCA) and increased expression of wild-type ?
Gene_expression (expression) of SNCA
7) Confidence 0.59 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920329 Disease Relevance 1.17 Pain Relevance 0.05
Similarly, mutations in the SNCA, or Synuclein-Alpha (non-A4 component of amyloid precursor) gene [40] as well as the overproduction of ?
Gene_expression (overproduction) of SNCA associated with alzheimer's dementia
8) Confidence 0.58 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2965495 Disease Relevance 0.66 Pain Relevance 0
These siRNAs were screened for their ability to silence the expression of a transiently co-transfected enhanced green fluorescent protein-human SNCA fusion construct (pEGFP-NACP) in BE(2)-M17 human neuroblastoma cells.
Gene_expression (expression) of NACP associated with neuroblastoma
9) Confidence 0.58 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2612658 Disease Relevance 0.10 Pain Relevance 0
Dystrophic axonal morphology is present in the striatum of AAV1/2 A53T alpha-synuclein injected rats
Gene_expression (injected) of A53T alpha-synuclein (A53T) in striatum
10) Confidence 0.50 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC2984491 Disease Relevance 0 Pain Relevance 0.04
Nigral delivery of AAV1/2-A53T alpha-synuclein and AAV1/2-GFP produce neuronal loss in the SN
Gene_expression (/) of A53T alpha-synuclein (A53T) in neuronal associated with substantia nigra
11) Confidence 0.50 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC2984491 Disease Relevance 0.07 Pain Relevance 0.27
Delivery with AAV1/2-A53T alpha-synuclein produced a 42% and a 29% decrease in NeuN-immunoreactive cells compared to AAV1/2-empty vector (P < 0.01) and AAV1/2-GFP (P < 0.01) treated groups respectively.
Gene_expression (produced) of A53T alpha-synuclein (A53T)
12) Confidence 0.50 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC2984491 Disease Relevance 0.09 Pain Relevance 0.16
We examined mRNA expression levels of DA transporter (DAT), tyrosine hydroxylase (TH), dopamine D2 receptor, alpha-synuclein, and nuclear receptor-related 1 (Nurr1) in discrete mesocorticolimbic and nigrostriatal subpopulations of heroin users and control subjects.
Spec (examined) Gene_expression (expression) of alpha-synuclein associated with dopamine and opiate addiction
13) Confidence 0.45 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 18057194 Disease Relevance 0.25 Pain Relevance 0.42
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

Background

Gene_expression (Expression) of A53T alpha-synuclein (A53T) in substantia nigra associated with substantia nigra and disease
14) Confidence 0.44 Published 2010 Journal Mol Neurodegener Section Title Doc Link PMC2984491 Disease Relevance 0.51 Pain Relevance 0.13
Expression of GFP and human A53T alpha-synuclein along the nigrostriatal path
Gene_expression (Expression) of A53T alpha-synuclein (A53T)
15) Confidence 0.44 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC2984491 Disease Relevance 0.22 Pain Relevance 0.24
Mutations described for these familial forms of PD, include autosomal dominant mutations of alpha-synuclein gene (PARK1) (Polymeropoulos et al., 1997), uchl1 gene (PARK5) and lrrk2 gene (PARK8) (Funayama et al., 2002) or autosomal recessive mutations of parkin gene (PARK2) (Kitada et al., 1998; Mizuno et al., 2008), pink1 gene (PARK6) (Hatano et al., 2004; Valente et al., 2004a), dj-1 gene (PARK7) (Bonifati et al., 2003) and atp13a2 gene (PARK9) (Ramirez et al., 2006).
Gene_expression (mutations) of PARK1 associated with disease
16) Confidence 0.06 Published 2010 Journal Frontiers in Aging Neuroscience Section Body Doc Link PMC2890153 Disease Relevance 0.99 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox